DOJ reclassifies medical marijuana to Schedule III
Federal reclassification opens medical cannabis to research and tax relief
Federal reclassification opens medical cannabis to research and tax relief
On April 23, 2026, the Trump Justice Department announced an immediate order reclassifying FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This represents the first federal reclassification of marijuana since its placement in Schedule I by President Nixon in 1970. The action was directed by Trump's December 18, 2025 executive order on medical marijuana and CBD research.
Essential concepts and terms to understand this topic
Legal principle that minor violations or values below a certain threshold are too trivial to enforce.
State-controlled liquor regulations established after Prohibition''s repeal
A drug pricing policy requiring companies to charge U.S. programs no more than their lowest price charged in any other country.
Constitutional repeal of the nationwide alcohol ban
State authority to control alcohol sales granted by the 21st Amendment
The only amendment to repeal another; it ended the nationwide alcohol ban (18th Amendment) and gave states broad authority to regulate alcohol sales, distribution, and consumption.
Federal law supersedes conflicting state or local law under the Supremacy Clause.
Powers not explicitly given to the federal government and not forbidden to the states, which remain under state control.
Power is divided between the federal government and state governments, each exercising authority in designated areas.
Congressional authority to raise revenue and allocate federal funds
Executive branch directing DEA and DOJ reclassification
Trump issued a December 18, 2025 executive order directing federal agencies to increase medical marijuana and CBD research and consider reclassification. On April 23, 2026, the DOJ announced the immediate Schedule III reclassification of medical marijuana and initiated the expedited hearing process for all marijuana, demonstrating sustained executive direction on this policy shift.
Federal agency implementing reclassification and conducting administrative hearing
The DEA executed the April 23 order reclassifying medical marijuana and is conducting the formal rulemaking process for broader reclassification. The June 29, 2026 hearing represents the DEA's key role in shaping the final scope and timing of the reclassification.
Initiated marijuana reclassification policy
Trump's December 2025 executive order directed DOJ to begin marijuana reclassification based on treaty obligations. This executive direction set the timeline and methodology, instructing use of the treaty pathway to bypass APA notice-and-comment.
Contact your House Representative to push for federal cannabis business tax relief codification
civic action
The removal of Section 280E restrictions is a regulatory change that could be reversed by future administrations. Congress should codify cannabis business tax relief in statute to make it permanent. Call your representative to ask them to support legislation ensuring state-legal cannabis businesses can deduct ordinary business expenses.
Contact your Senators about supporting the June 29 DEA hearing on full marijuana reclassification
civic action
The DEA is holding a formal administrative hearing on June 29, 2026 to consider reclassifying all marijuana (including recreational) from Schedule I to Schedule III. This hearing will shape federal drug policy for years. Contact your senators to urge them to support evidence-based reclassification and public participation in the hearing process.
Engage with cannabis industry advocacy groups on tax relief implementation and regulatory clarity
civic action
Cannabis industry groups are working to implement the Section 280E tax relief and ensure IRS guidance reflects the new Schedule III status. Join advocacy efforts to push for clear regulatory guidance from the IRS on deduction procedures, recordkeeping, and compliance timelines.
True
On April 23, 2026, the DOJ announced marijuana would move from Schedule I to Schedule III.
The Trump administration announced the immediate reclassification of FDA-approved and state-licensed medical marijuana to Schedule III on April 23, 2026.
Sources
True
This action was directed by Trump's December 18, 2025 executive order on medical marijuana and CBD research.
Trump issued an executive order in December 2025 directing federal agencies to increase medical marijuana and CBD research and consider reclassification.
Sources
True
Schedule III drugs have accepted medical use and lower abuse potential than Schedule I drugs.
Schedule III is defined by the CSA as drugs with accepted medical use and abuse potential lower than Schedules I and II. Examples: ketamine, anabolic steroids.
Sources
True
Removing IRS Section 280E will allow cannabis businesses to deduct ordinary business expenses for the first time.
Section 280E prohibits deductions for Schedule I/II drug businesses. Reclassification to Schedule III removes this restriction, though there may be transitions in IRS guidance.
Sources
True
38 states and Washington, DC have legalized some form of medical or recreational marijuana.
As of 2026, a significant majority of U.S. states have enacted medical or recreational cannabis legalization.
Sources
True
The DEA administrative hearing on marijuana reclassification begins on June 29, 2026.
The Trump administration announced an expedited hearing on full marijuana reclassification set to begin June 29, 2026, replacing the Biden-era proceedings.
Sources
False
Biden's administration completed a marijuana reclassification in 2024.
Biden's DEA initiated rulemaking in May 2024 with a notice of hearing set for August 2024, but the process was never completed before the change in administration.
Sources
False
Reclassifying marijuana to Schedule III is the same as legalizing it.
Schedule III still keeps marijuana as a controlled substance with federal restrictions. Legalization would require removal from the CSA or legislative action.
Sources